Article metrics

Download PDFPDF
Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate

 

Online download statistics by month:

Online download statistics by month: November 2017 to September 2022

AbstractFullPdf
Nov 201710805539
Dec 20175064125
Jan 20185004221
Feb 20184273517
Mar 20182913211
Apr 20182452612
May 2018176125
Jun 201815272
Jul 201816885
Aug 201814182
Sep 201817034
Oct 20182091711
Nov 20181791510
Dec 201813595
Jan 2019118129
Feb 20199368
Mar 20199666
Apr 20197331
May 20198841
Jun 20193711
Jul 20195011
Aug 20193310
Sep 20197833
Oct 20195431
Nov 20193353
Dec 20194410
Jan 20206042
Feb 20205802
Mar 20203101
Apr 20204440
May 20205251
Jun 20202610
Jul 20207155
Aug 2020806
Sep 20204332
Oct 20204240
Nov 20202322
Dec 20203900
Jan 20212610
Feb 20214222
Mar 20212941
Apr 20216012
May 20212600
Jun 2021001
Jul 2021621
Aug 2021110
Sep 2021510
Oct 20213522
Nov 20213024
Dec 20216030
Jan 20223331
Feb 20225000
Mar 20224502
Apr 20223401
May 20228722
Jun 20225811
Jul 20222823
Aug 20227412
Sep 20226732
Total6469415251